Differentstudies showed that while this axis is augmented in about50% of ALL cases, applying different c-Myc inhibitorsincreases cell death and is an effective therapeutic optionfor ALL patients(Delgado and León, 2010; Roderick et al.,2014). The gene discussed is MYC; the disease is acute lymphoblastic leukemia.